[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546861":3},{"organization":4,"armGroups":7,"interventions":49,"overallOfficials":72,"centralContacts":76,"locations":85,"responsibleParty":297,"collaborators":61,"id":299,"slug":300,"hasResults":301,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":61,"eligibilityCriteria":305,"healthyVolunteers":301,"sex":306,"minAge":307,"maxAge":61,"enrollmentInfo":308,"targetDuration":61,"studyType":311,"phases":312,"briefSummary":314,"conditions":315,"keywords":323,"overallStatus":88,"whyStopped":61,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14,18,23,27,31,36,41,46],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4170156 (Dose-escalation, Cohort A1)","EXPERIMENTAL","Escalating doses of LY4170156 administered intravenously (IV)",[13],"Drug: LY4170156",{"label":15,"type":10,"description":16,"interventionNames":17},"LY4170156 (Cohort A1 Parts A and C)","LY4170156 administered IV",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"LY4170156 Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B)","LY4170156 administered IV and itraconazole administered orally",[13,22],"Drug: Itraconazole",{"label":24,"type":10,"description":25,"interventionNames":26},"LY4170156 (Dose-optimization, Cohort A2)","Comparing 2 or more doses (evaluated during dose escalation) of LY4170156 administered IV",[13],{"label":28,"type":10,"description":29,"interventionNames":30},"LY4170156 (Enrichment Cohort A3)","Monotherapy administered IV",[13],{"label":32,"type":10,"description":33,"interventionNames":34},"LY4170156 (Combination Cohort A4)","Combination with bevacizumab administered IV",[13,35],"Drug: bevacizumab",{"label":37,"type":10,"description":38,"interventionNames":39},"LY4170156 (Combination Cohort A5)","Combination with carboplatin administered IV",[13,40],"Drug: carboplatin",{"label":42,"type":10,"description":43,"interventionNames":44},"LY4170156 Combination with Pembrolizumab (Dose-optimization Cohort A6)","Comparing 2 or more doses (evaluated during dose escalation) of LY4170156 administered IV with pembrolizumab",[13,45],"Drug: pembrolizumab",{"label":47,"type":10,"description":16,"interventionNames":48},"LY4170156 (Dose-expansion, Cohort B1-B4)",[13],[50,57,62,65,69],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"DRUG","LY4170156","Intravenous",[15,32,37,9,47,24,28,19,42],[56],"sofetabart mipitecan",{"type":51,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"bevacizumab","IV",[32],null,{"type":51,"name":63,"description":59,"armGroupLabels":64,"otherNames":61},"carboplatin",[37],{"type":51,"name":66,"description":67,"armGroupLabels":68,"otherNames":61},"Itraconazole","oral",[19],{"type":51,"name":70,"description":59,"armGroupLabels":71,"otherNames":61},"pembrolizumab",[42],[73],{"name":74,"affiliation":5,"role":75},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[77,82],{"name":78,"role":79,"phone":80,"phoneExt":61,"email":81},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":83,"role":79,"phone":61,"phoneExt":61,"email":84},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[86,100,110,120,130,138,144,154,164,174,185,189,200,209,218,229,237,248,257,263,268,279,288],{"facility":87,"status":88,"city":89,"state":90,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":99,"contacts":61},"HonorHealth","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":95,"coordinates":96},"Point",[97,98],-111.89903,33.50921,{"lat":98,"lon":97},{"facility":101,"status":88,"city":102,"state":103,"zip":104,"country":92,"countryCode":93,"cosmosGeoPoint":105,"geoPoint":109,"contacts":61},"University of California, San Diego (UCSD) - Moores Cancer Center","La Jolla","California","92037",{"type":95,"coordinates":106},[107,108],-117.2742,32.84727,{"lat":108,"lon":107},{"facility":111,"status":88,"city":112,"state":113,"zip":114,"country":92,"countryCode":93,"cosmosGeoPoint":115,"geoPoint":119,"contacts":61},"South Texas Accelerated Research Therapeutics (START) Midwest","Grand Rapids","Michigan","49546",{"type":95,"coordinates":116},[117,118],-85.66809,42.96336,{"lat":118,"lon":117},{"facility":121,"status":88,"city":122,"state":123,"zip":124,"country":92,"countryCode":93,"cosmosGeoPoint":125,"geoPoint":129,"contacts":61},"NYU Langone Health - Long Island","Mineola","New York","11501",{"type":95,"coordinates":126},[127,128],-73.64068,40.74927,{"lat":128,"lon":127},{"facility":131,"status":88,"city":123,"state":123,"zip":132,"country":92,"countryCode":93,"cosmosGeoPoint":133,"geoPoint":137,"contacts":61},"New York University (NYU) Clinical Cancer Center","10016",{"type":95,"coordinates":134},[135,136],-74.00597,40.71427,{"lat":136,"lon":135},{"facility":139,"status":88,"city":123,"state":123,"zip":140,"country":92,"countryCode":93,"cosmosGeoPoint":141,"geoPoint":143,"contacts":61},"David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center","10065",{"type":95,"coordinates":142},[135,136],{"lat":136,"lon":135},{"facility":145,"status":88,"city":146,"state":147,"zip":148,"country":92,"countryCode":93,"cosmosGeoPoint":149,"geoPoint":153,"contacts":61},"The Ohio State University (OSU) Wexner Medical Center","Columbus","Ohio","43210",{"type":95,"coordinates":150},[151,152],-82.99879,39.96118,{"lat":152,"lon":151},{"facility":155,"status":88,"city":156,"state":157,"zip":158,"country":92,"countryCode":93,"cosmosGeoPoint":159,"geoPoint":163,"contacts":61},"The University of Texas - MD Anderson Cancer Center","Houston","Texas","77030-4000",{"type":95,"coordinates":160},[161,162],-95.36327,29.76328,{"lat":162,"lon":161},{"facility":165,"status":88,"city":166,"state":167,"zip":168,"country":92,"countryCode":93,"cosmosGeoPoint":169,"geoPoint":173,"contacts":61},"START Mountain Region","West Valley City","Utah","84119",{"type":95,"coordinates":170},[171,172],-112.00105,40.69161,{"lat":172,"lon":171},{"facility":175,"status":88,"city":176,"state":61,"zip":177,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":61},"Cancer Research SA","Adelaide","5000","Australia","AU",{"type":95,"coordinates":181},[182,183],138.59863,-34.92866,{"lat":183,"lon":182},{"facility":186,"status":88,"city":187,"state":61,"zip":188,"country":178,"countryCode":179,"cosmosGeoPoint":61,"geoPoint":61,"contacts":61},"Icon Cancer Centre South Brisbane","QLD","4101",{"facility":190,"status":88,"city":191,"state":61,"zip":192,"country":193,"countryCode":194,"cosmosGeoPoint":195,"geoPoint":199,"contacts":61},"Centre Leon Berard","Lyon","69373","France","FR",{"type":95,"coordinates":196},[197,198],4.84789,45.74906,{"lat":198,"lon":197},{"facility":201,"status":88,"city":202,"state":61,"zip":203,"country":193,"countryCode":194,"cosmosGeoPoint":204,"geoPoint":208,"contacts":61},"Institut de Cancerologie de l'Ouest - site St-Herblain","Saint-Herblain","44805",{"type":95,"coordinates":205},[206,207],-1.651,47.21154,{"lat":207,"lon":206},{"facility":210,"status":88,"city":211,"state":61,"zip":212,"country":193,"countryCode":194,"cosmosGeoPoint":213,"geoPoint":217,"contacts":61},"Oncopole Claudius Regaud","Toulouse","31059",{"type":95,"coordinates":214},[215,216],1.44367,43.60426,{"lat":216,"lon":215},{"facility":219,"status":88,"city":220,"state":61,"zip":221,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":61},"Humanitas San Pio X","Milan","20159","Italy","IT",{"type":95,"coordinates":225},[226,227],9.18951,45.46427,{"lat":227,"lon":226},{"facility":230,"status":88,"city":220,"state":61,"zip":231,"country":222,"countryCode":223,"cosmosGeoPoint":232,"geoPoint":236,"contacts":61},"Istituto Europeo di Oncologia","20141",{"type":95,"coordinates":233},[234,235],12.59836,42.78235,{"lat":235,"lon":234},{"facility":238,"status":88,"city":239,"state":61,"zip":240,"country":241,"countryCode":242,"cosmosGeoPoint":243,"geoPoint":247,"contacts":61},"Shizuoka Cancer Center","Shizuoka","411-8777","Japan","JP",{"type":95,"coordinates":244},[245,246],138.38333,34.98333,{"lat":246,"lon":245},{"facility":249,"status":88,"city":250,"state":61,"zip":251,"country":241,"countryCode":242,"cosmosGeoPoint":252,"geoPoint":256,"contacts":61},"National Cancer Center Hospital","Tokyo","104-0045",{"type":95,"coordinates":253},[254,255],139.69171,35.6895,{"lat":255,"lon":254},{"facility":258,"status":88,"city":250,"state":61,"zip":259,"country":241,"countryCode":242,"cosmosGeoPoint":260,"geoPoint":262,"contacts":61},"Cancer Institute Hospital of JFCR","135-8550",{"type":95,"coordinates":261},[254,255],{"lat":255,"lon":254},{"facility":264,"status":88,"city":265,"state":61,"zip":266,"country":267,"countryCode":61,"cosmosGeoPoint":61,"geoPoint":61,"contacts":61},"National Cancer Center","Goyang-si Gyeonggi-do","10408","South Korea",{"facility":269,"status":88,"city":270,"state":61,"zip":271,"country":272,"countryCode":273,"cosmosGeoPoint":274,"geoPoint":278,"contacts":61},"Hospital Universitario Vall d'Hebron","Barcelona","08035","Spain","ES",{"type":95,"coordinates":275},[276,277],2.15899,41.38879,{"lat":277,"lon":276},{"facility":280,"status":88,"city":281,"state":61,"zip":282,"country":272,"countryCode":273,"cosmosGeoPoint":283,"geoPoint":287,"contacts":61},"Hospital Universitario 12 de Octubre","Madrid","28041",{"type":95,"coordinates":284},[285,286],-3.70256,40.4165,{"lat":286,"lon":285},{"facility":289,"status":88,"city":290,"state":61,"zip":291,"country":272,"countryCode":273,"cosmosGeoPoint":292,"geoPoint":296,"contacts":61},"Hospital Clinico Universitario de Valencia","Valencia","46010",{"type":95,"coordinates":293},[294,295],-0.37966,39.47391,{"lat":295,"lon":294},{"type":298,"investigatorFullName":61,"investigatorTitle":61,"investigatorAffiliation":61,"oldNameTitle":61,"oldOrganization":61},"SPONSOR","100546861","phase-1-a-study-of-ly4170156-in-participants-with-selected-advanced-solid-tumors-100546861",false,"NCT06400472","A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","A First-in-Human, Phase 1a\u002F1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)\n  * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer\n  * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n* Individual with history of carcinomatous meningitis\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n* History of pneumonitis\u002Finterstitial lung disease\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","ALL","18 Years",{"count":309,"type":310},495,"ESTIMATED","INTERVENTIONAL",[313],"PHASE1","The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",[316,317,318,319,320,321,322],"Ovarian Neoplasms","Endometrial Neoplasms","Uterine Cervical Neoplasms","Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Neoplasms","Pancreatic Neoplasm","Colorectal Neoplasms",[324,325,326,327,328,329,330,331,332,333,334,335,336,337],"Folate receptor alpha","NSCLC","Ovarian cancer","Cervical cancer","Endometrial cancer","Solid tumor","Lung cancer","Breast cancer","Pancreatic cancer","Colorectal cancer","Anti-drug conjugate","Phase I","Chemotherapy","sofe-m","2026-06-17",{"date":340,"type":341},"2026-06-18","ACTUAL",{"date":343,"type":341},"2024-05-20",{"date":345,"type":310},"2027-04",{"name":5,"class":6},23]